Harvard Bioscience (HBIO) Reports In-Line Q2 EPS

Harvard Bioscience (NASDAQ: HBIO) reported Q2 EPS of $0.06, in-line with the analyst estimate of $0.06. Revenue for the quarter came in at $25.4 million versus the consensus estimate of $25.46 million.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c